Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
about
Hormone therapy for preventing cardiovascular disease in post-menopausal womenHormone therapy for preventing cardiovascular disease in post-menopausal womenLong term hormone therapy for perimenopausal and postmenopausal womenLung cancer: epidemiology, etiology, and preventionEstrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDsThe Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the RiskNonadherence to treatment protocol in published randomised controlled trials: a reviewPostmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspectiveSex differences in stroke: the contribution of coagulationLong-term hormone therapy for perimenopausal and postmenopausal women.New evidence for cardiac benefit of postmenopausal hormone therapy.Advances in the treatment of menopausal symptoms.The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk.Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer riskRecent trends in breast cancer incidence in US white women by county-level urban/rural and poverty status.Observations following discontinuation of long-term denosumab therapy.Mammographic screening and risk factors for breast cancerGrowth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.Factors associated with successful discontinuation of hormone therapy.Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cellsLung cancer and hormone replacement therapy: association in the vitamins and lifestyle studyPrimary and secondary prevention of colorectal cancerExposure to statins and risk of common cancers: a series of nested case-control studies.Intent-to-Treat vs. Non-Intent-to-Treat Analyses under Treatment Non-Adherence in Mental Health Randomized Trials.Mammographic breast density and tolerance for short-term postmenopausal hormone therapy suspensionThe 2012 hormone therapy position statement of: The North American Menopause Society.Chains of evidence, mosaics of data: does estrogen 'cause' breast cancer? How would we know?Effects of adenosine monophosphate used in combination with L-arginine on female rabbit corpus cavernosum tissueMenopausal hormone therapy and cancer: changing clinical observations of target site specificity.Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke.Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative.Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapyConceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI-BDStratified pathway analysis to identify gene sets associated with oral contraceptive use and breast cancer.Hyaluronic acid prevents immunosuppressive drug-induced ovarian damage via up-regulating PGRMC1 expression.Breast cancer after use of estrogen plus progestin in postmenopausal women.A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age.
P2860
Q24187326-D2A0B96A-308C-4070-89C6-E0235A3DE129Q24197712-FA8F7B15-43F3-4CE8-A183-946641D683F8Q24201974-F560C0C9-F477-45FA-87BC-93E9045469B4Q24630167-5252A883-84B9-4776-AF41-D67C6638F521Q24658109-8F2B721E-2ED0-4675-8FBB-5F6F97E601C5Q26800279-B232083F-F7A3-4560-8F20-082AD6E959BEQ26821782-8A325461-53A9-49D6-B783-5DD29C775846Q26825321-59D8AB30-504E-4AE7-8FE3-64BC1339635EQ26864207-C24D5B65-A352-44F8-8222-6965E8858116Q27022768-D841F230-2676-4CAB-BEED-F09FF9B72281Q30238978-110F8EDE-4E65-46C0-9447-A19FB7F01F6FQ30396979-BB6465C3-D1BB-43FE-8F90-9A674AE00028Q30448720-8B17F66C-2BAB-47AF-93DB-161649FE89B1Q30485457-9AD66790-A2B7-41A2-BEDE-A5C1622670E3Q30491822-2284611A-EDD9-4A88-934D-A83181784260Q33475114-29847FA2-0C58-4DE6-8F59-67476CB4F256Q33563846-CC297378-8596-4EC6-84A6-DC2232303741Q33566626-2598067D-4CF4-46EC-916D-CA54D189A2F6Q33569159-0DF3D7C0-D952-4D2B-85E6-B21B5B404DB1Q33571609-6192E060-756D-45F8-A31D-0C6DAE8131C2Q33711732-2A0553BF-2B7E-48BE-857E-DF0EB3D47861Q33770389-2A90704E-532F-4B7A-87E3-5EF0E2FAFF04Q33976246-2F341B99-8CA1-4360-9649-D0314C578A6AQ34028899-5E53A4F3-8E28-4D7A-A97A-2942D8E37478Q34066072-47A4121C-DE30-40EE-BD35-93C67FCD8C91Q34137122-7F426CB7-1C69-436F-81DE-6719F83EFFC2Q34161400-DB3F1AC0-D886-408A-8A53-3291951C824FQ34285969-B03DD4E9-C77B-48E7-A8C9-7906E7465F9FQ34286586-B20A7169-9AAB-400F-9A4C-6642B92B0221Q34315478-5C0A4260-8EEC-416F-ACB0-461203EE4D72Q34321877-7BC0BE90-8AFB-4F6A-8C6C-9F84074A80C7Q34370566-156CE1EE-A581-42ED-8B0A-A6A0F2B118F3Q34420014-8A3B25AD-21EF-4AD7-9B0C-19CDDCD34B4BQ34449454-A2902008-2A24-411D-884F-B2A5F388F60BQ34475143-C0F31C3A-18BF-41A2-A496-5224948B165EQ34575982-008D8DCF-1099-40D6-A1F0-194543D37608Q34680457-C902353A-486D-482D-BBAB-6F164EB7BC85Q34830224-223F69BC-8F1C-43F4-9F83-4FE064EC905BQ34938322-64350391-2773-4E10-AA7E-DF615595AA27Q35035445-8B50DD64-672E-4B33-90F8-CED841F7727E
P2860
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Health risks and benefits 3 ye ...... t with estrogen and progestin.
@ast
Health risks and benefits 3 ye ...... t with estrogen and progestin.
@en
Health risks and benefits 3 ye ...... t with estrogen and progestin.
@nl
type
label
Health risks and benefits 3 ye ...... t with estrogen and progestin.
@ast
Health risks and benefits 3 ye ...... t with estrogen and progestin.
@en
Health risks and benefits 3 ye ...... t with estrogen and progestin.
@nl
prefLabel
Health risks and benefits 3 ye ...... t with estrogen and progestin.
@ast
Health risks and benefits 3 ye ...... t with estrogen and progestin.
@en
Health risks and benefits 3 ye ...... t with estrogen and progestin.
@nl
P2093
P356
P1476
Health risks and benefits 3 ye ...... t with estrogen and progestin.
@en
P2093
Aaron Aragaki
Andrea LaCroix
Garnet L Anderson
Jacques Rossouw
JoAnn E Manson
Marcia L Stefanick
Margery Gass
Robert Brzyski
Robert Wallace
Ross L Prentice
P304
P356
10.1001/JAMA.299.9.1036
P407
P577
2008-03-01T00:00:00Z